← Back
Data updated: Mar 10, 2026
RHYTHM
MetabolicCardiovascularInfectious Disease
RHYTHM is a pharmaceutical company focused on Metabolic, Cardiovascular, Infectious Disease. Key products include IMCIVREE.
2020
Since
1
Drugs
-
Trials
2
Approved (2yr)
Recent Activity
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Metabolic 91%
1 drugs Phase 3: 7 Phase 2: 8 Phase 1: 1
Cardiovascular 7%
0 drugs Phase 3: 1
Infectious Disease 2%
0 drugs Phase 1: 1
Pipeline Strength Pro
Loading...
Competitors Pro
Merck big-pharma
Infectious Disease, Cardiovascular, Metabolic
Johnson & Johnson big-pharma
Infectious Disease, Cardiovascular, Metabolic
B BRAUN specialty
Infectious Disease, Metabolic, Cardiovascular
Novo Nordisk big-pharma
Metabolic, Cardiovascular, Infectious Disease
AZURITY specialty
Cardiovascular, Metabolic, Infectious Disease
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2020-11-25
- Latest
- 2025-08-21
- Applications
- 1